Pharma & Biotech
Showing 1–12 of 35 results
- May 5, 2024
Novartis has made significant progress in its pipeline development and regulatory milestones, demonstrating its commitment to innovation and pipeline progression.
- April 30, 2024
Twist Bioscience’s synthetic genes are a crucial part of its revenue stream, accounting for approximately 30% of total revenue.
- April 24, 2024
Agilent Technologies has introduced the ProteoAnalyzer system, an innovative automated parallel capillary electrophoresis solution for protein analysis, which strengthens the company’s competitive positioning in the analytical instruments space.
- April 19, 2024
Takeda Pharmaceutical’s increasing research and development (R&D) expenses potentially impacting its profitability and the importance of a robust product pipeline is supported by the provided sources.
- April 19, 2024
The company has entered an exclusive development and commercialization deal with Coya Therapeutics for their investigational combination biologics for the treatment of neurodegenerative disease, ALS.
- April 18, 2024
The company’s diversified segment, which includes the neurology, dermatology, and generics businesses, is subject to competitive and pricing pressures in diversified segments.
- April 18, 2024
BioNTech reported a significant decline in its fourth-quarter profit and sales, which fell short of analysts’ expectations due to falling demand for COVID-19 vaccines. This decline was attributed to inventory write-downs by BioNTech’s collaboration partner, Pfizer.
- April 12, 2024
The challenges faced by MDT in RAS market include integrating AI and automation in surgery, which raises many ethical challenges that warrant careful consideration.
- April 11, 2024
Merck’s oncology business, spearheaded by its flagship product KEYTRUDA, showcases the company’s proficiency in developing and marketing innovative and commercially successful therapies.
- April 11, 2024
In clinical studies, Solensia has shown that a total of 76% of cat owners reported sustained improvement in signs of pain when their cats were treated with Solensia.
- April 8, 2024
Teva is strategically positioning itself to introduce five biosimilars within the next four years, targeting key medications like Humira and Stelara.
- April 4, 2024
Boston Scientific reported excellent results for 2023, with one of the strongest years in the company’s history. The company’s total operational sales grew by 15% in Q4 2023 and 13% for the full year, exceeding its financial goals.